Efficacy and safety study of olmesartan medoxomil, amlodipine, and hydrochlorothiazide combination therapy in patients with hypertension not controlled with olmesartan medoxomil and hydrochlorothiazide combination therapy: Results of a randomized, double-blind, multicenter trial
- Authors
- Sohn, I.S.; Kim, C.-J.; Oh, B.-H.; Hong, T.-J.; Park, C.-G.; Kim, B.-S.; Chung, W.-B.; Nam, C.-W.; Kim, C.-H.; Choi, D.-J.; Baek, S.-H.; Kim, W.-S.; Ahn, T.-H.; Cho, J.-H.; Hwang, H.-K.; Shin, E.-S.; Shin, J.-H.; Jeong, M.-H.; Jeong, J.-O.; Bae, J.-H.; Lee, S.-H.; Rim, S.-J.; Rhew, J.-Y.; Kim, D.-I.; Kim, D.-K.; Kim, S.-K.; Seo, H.-S.; Kang, D.-H.; Kim, Y.-D.; Kim, D.-W.; Ha, J.-W.; Park, W.-J.; Kim, T.H.; Kim, K.-S.; Park, S.-W.; Shim, W.-J.; Yang, J.-Y.; Choi, J.-W.; Lee, S.-H.; Ahn, J.-C.; Lee, K.
- Issue Date
- Dec-2016
- Publisher
- Springer International Publishing
- Citation
- American Journal of Cardiovascular Drugs, v.16, no.2, pp 129 - 138
- Pages
- 10
- Journal Title
- American Journal of Cardiovascular Drugs
- Volume
- 16
- Number
- 2
- Start Page
- 129
- End Page
- 138
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/64109
- DOI
- 10.1007/s40256-015-0156-x
- ISSN
- 1175-3277
1179-187X
- Abstract
- Background: This study was to evaluate the efficacy and safety of triple fixed-dose combination (FDC) therapy with olmesartan medoxomil (OM) 20 mg, amlodipine (AML) 5 mg, and hydrochlorothiazide (HCTZ) 12.5 mg (OM/ AML/HCTZ 20/5/12.5) in Korean patients with moderate hypertension not controlled with dual FDC therapy (OM/ HCTZ 20/12.5). Methods: In this multicenter, randomized, double-blind, parallel-group study, Korean patients aged 20 to 75 years with stage 2 hypertension who had a mean seated diastolic blood pressure (msDBP) ≥ 100 mmHg were enrolled when their BP was uncontrolled [mean seated systolic BP (msSBP)/msDBP > 140/90 mmHg or msSBP/msDBP > 130/80 mmHg with diabetes or chronic kidney disease] with 4-week dual FDC therapy (OM/HCTZ 20/12.5). The patients were randomized to receive either OM/AML/ HCTZ 20/5/12.5 or OM/HCTZ 20/12.5 once daily for 8 weeks. At the end of 8 weeks, patients with uncontrolled BP were assigned to receive either OM/AML/HCTZ 40/5/ 12.5 or OM/AML/HCTZ 20/5/12.5 in an additional 8-week open-label extension period. Results: A total of 623 patients received a 4-week run-in treatment with OM/HCTZ, 341 patients were randomized, and finally, 167 patients in the OM/AML/HCTZ group and 171 patients in the OM/HCTZ group were analyzed for the full analysis set. Non-responders after the 8 weeks of double-blind treatment continued the 8-week open-label treatment with OM/AML/HCTZ 40/5/12.5 mg (n = 32) or OM/AML/HCTZ 20/5/12.5 mg (n = 71). After 8 weeks of double-blind treatment, the changes in msDBP were -9.50 (8.46) mmHg in the OM/AML/HCTZ group and -4.23 (7.41) mmHg in the OM/HCTZ group (both p<0.0001 vs. baseline p<0.0001 between groups). The response rates for both msSBP and msDBP at week 8 were 65.27 % in the OM/AML/HCTZ group and 37.43 % in the OM/HCTZ group (p<0.0001 between groups). The response rates for both msSBP and msDBP at week 16 after open-label treatment were 18.75 % in the OM/AML/HCTZ 40/5/12.5 group and 46.48 % in the OM/AML/HCTZ 20/5/12.5 group (p = 0.0073 between groups). All medications were well tolerated. Conclusion: In Korean patients with moderate hypertension not controlled with dual FDC therapy (OM/HCTZ 20/12.5) as first-line therapy, switching to triple FDC therapy (OM/AML/HCTZ 20/5/12.5) was associated with significant BP reductions and greater achievement of BP goals, and was well tolerated (ClinicalTrials.gov Identifier: NCT01838850). © The Author(s) 2015.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.